The triple GLP1R/GCGR/GIPR agonist, efocipegtrutide (HM15211), distinguished by its prolonged duration of action, which is attributed to a non-peptidyl flexible linker, is being investigated in a phase 2 clinical trial for MASH (217 participants, aged 18–70 years, across multiple US sites with an expected completion date in November 2025) [57], and a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD has been reported (66 participants, aged 18–65 years) [58]. The gene discussed is GCGR; the disease is metabolic dysfunction-associated steatotic liver disease.